Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Common Equity (2018 - 2025)

TransMedics (TMDX) has 8 years of Common Equity data on record, last reported at $473.1 million in Q4 2025.

  • For Q4 2025, Common Equity rose 106.95% year-over-year to $473.1 million; the TTM value through Dec 2025 reached $473.1 million, up 106.95%, while the annual FY2025 figure was $473.1 million, 106.95% up from the prior year.
  • Common Equity reached $473.1 million in Q4 2025 per TMDX's latest filing, up from $355.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $473.1 million in Q4 2025 and bottomed at $50.9 million in Q2 2022.
  • Average Common Equity over 5 years is $181.1 million, with a median of $173.4 million recorded in 2022.
  • Peak YoY movement for Common Equity: tumbled 42.78% in 2022, then surged 221.52% in 2023.
  • A 5-year view of Common Equity shows it stood at $67.9 million in 2021, then soared by 176.14% to $187.4 million in 2022, then decreased by 26.78% to $137.2 million in 2023, then skyrocketed by 66.62% to $228.6 million in 2024, then soared by 106.95% to $473.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $473.1 million in Q4 2025, $355.2 million in Q3 2025, and $318.1 million in Q2 2025.